Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 8/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067895 | 0.85 | GBA1 (0.51) | SLC1A3SLC1A2SLC1A1GBA1 | |
| SCHEMBL3862569 | 0.85 | GBA1 (0.51) | SLC1A3SLC1A2SLC1A1GBA1 | |
| SCHEMBL3852094 | 0.85 | GBA1 (0.51) | SLC1A3SLC1A2SLC1A1GBA1 | |
| SCHEMBL2243560 | 0.84 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2243565 | 0.84 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15841410 | 0.84 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL15841411 | 0.84 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL810701 | 0.84 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7089076 | 0.84 | GBA1 (0.50) | SLC1A3SLC1A2SLC1A1GBA1 | |
| SCHEMBL809775 | 0.83 | SPPL2A (0.47) | PGRNR3C1CNR1ACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399895-B1 | Process for producing optically active aliphatic fluoroalcohol | KANTO KAGAKU (JP) | 2018-08-08 | — | — | EP | disclosed |
| US-8558033-B2 | Process for producing optically active aliphatic fluoroalcohol | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2013-10-15 | — | — | US | disclosed |
| US-20110319671-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL | KANTO KAGAKU KABUSHIKI KAISHA (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2399895-A2 | Process for producing optically active aliphatic fluoroalcohol | Kanto Kagaku Kabushiki Kaisha (JP) | 2011-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319671-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALIPHATIC FLUOROALCOHOL | ADH1A, ADH1C, ADH5 | SLC1A3 2827/4885SLC1A2 2106/4885SLC1A1 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.